Bellicum Pharmaceuticals, Inc.’s BLCMannounced that FDA has lifted clinical hold on studies conducted in the United States evaluating its T cell therapy, BPX-501. The company consulted with regulatory body and agreed to make amendments to the study protocols, which include guidance on monitoring and management of neurologic adverse events.
FDA Lifts Clinical Hold on Bellicum's (BLCM) T Cell Therapy
Понравилась статья? Подпишитесь на канал, чтобы быть в курсе самых интересных материалов
Подписаться